{
  "docId": "019de073-7cac-75f7-8c4d-c1df42c29745",
  "docSlug": "674201d8cef93b1820f78aa5772cd90f",
  "documentTitle": "ATAI | Investor Presentation Deck | 36 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 36,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 16,
  "notes": "The table uses checkmarks to indicate the presence of favorable attributes across different drug classes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7cac-75f7-8c4d-c1df42c29745/29",
  "deckHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745",
  "deckJsonHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745.json",
  "deckAnchorHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.04,
        "y": 0.35
      },
      "kind": "list",
      "text": "SSRI's are current standard of care for GAD but require 4-6 weeks for onset of effect and have several disadvantages: 1. SSRI/SNRI-specific inadequacy 2. Lack of tolerability 3. Patient nonadherence to medications that fail to relieve symptoms of anxiety quickly",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f5b83d0-221c-46c2-867c-5931555f7f48",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.04,
        "y": 0.75
      },
      "kind": "list",
      "text": "Benzodiazepines are second-line treatment, offering fast and effective relief, but carrying significant risk of: 1. Sedation 2. Impaired cognition 3. Dependence/addiction",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6160ff8-d13e-4875-85da-e73fffbd116a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.2,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "There is an unmet need in GAD for therapies with rapid onset, high efficacy, and minimal side effects",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6fe43b7e-961b-4e0a-bc31-fc4170275e92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.26,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Note: GABA = Gamma aminobutyric acid, SERT = serotonin transporter, NET = serotonin transporter, MoA = Mechanism of Action; 5HT1a = serotonin 1A receptor; VDCC = voltage dependent calcium channel; TSPO = mitochondrial translocator protein Source: GlobalData, Evaluate Pharma (both as of 19.03.2021) (1) DeMartini et al., “Generalized Anxiety Disorder” (2019)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b505c7d-e150-467b-a379-d0f4d8bbeb27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.7,
        "x": 0.26,
        "y": 0.22
      },
      "kind": "table",
      "text": "Comparison table of therapeutic options for GAD",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca9f0618-6dfb-4fb2-8209-e1dd01a8b34d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.26,
        "y": 0.06
      },
      "kind": "title",
      "text": "GRX-917 can fill unmet need in Generalized Anxiety Disorder (GAD) with rapid onset and favorable safety profile",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfb2c6ec-50fb-4a6f-9003-b582ba76b66c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "eede1355-a369-4472-aa53-2534dea52456",
      "evidence": "Table comparing product features against competitors",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}